EMEA-001410-PIP02-17-M03
Key facts
| Invented name |
Ninlaro
|
| Active substance |
Ixazomib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0351/2020
|
| PIP number |
EMEA-001410-PIP02-17-M03
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of lymphoid malignancies (excluding multiple myeloma)
|
| Route(s) of administration |
|
| Contact for public enquiries |
Takeda Pharm A/S
E-mail: medinfoEMEA@takeda.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|